Alan Sandler

43.1k total citations · 9 hit papers
163 papers, 23.8k citations indexed

About

Alan Sandler is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Alan Sandler has authored 163 papers receiving a total of 23.8k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Oncology, 102 papers in Pulmonary and Respiratory Medicine and 36 papers in Molecular Biology. Recurrent topics in Alan Sandler's work include Lung Cancer Treatments and Mutations (91 papers), Lung Cancer Research Studies (57 papers) and Colorectal Cancer Treatments and Studies (36 papers). Alan Sandler is often cited by papers focused on Lung Cancer Treatments and Mutations (91 papers), Lung Cancer Research Studies (57 papers) and Colorectal Cancer Treatments and Studies (36 papers). Alan Sandler collaborates with scholars based in United States, France and Spain. Alan Sandler's co-authors include Joan H. Schiller, Chandra P. Belani, David H. Johnson, David H. Johnson, Julie R. Brahmer, Robert J. Gray, Afshin Dowlati, Michael C. Perry, Rogério Lilenbaum and Corey J. Langer and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Alan Sandler

161 papers receiving 23.3k citations

Hit Papers

Paclitaxel–Carboplatin Al... 2002 2026 2010 2018 2006 2002 2018 2003 2016 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
    2006 4.5k citations Alan Sandler, Robert J. Gray et al. profile →
  2. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
    2002 4.1k citations Joan H. Schiller, Chandra P. Belani et al. profile →
  3. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
    2018 2.6k citations Mark A. Socinski, Robert M. Jotte et al. profile →
  4. Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
    2003 2.1k citations Roy S. Herbst, Chandra P. Belani et al. profile →
  5. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
    2016 2.1k citations Alexander I. Spira, Marcus Ballinger et al. profile →
  6. TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer
    2005 1.2k citations Roy S. Herbst, Alan Sandler et al. profile →
  7. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
    2019 1.1k citations Howard West, Achim Rittmeyer et al. profile →
  8. Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer
    2006 500 citations Corey J. Langer, Alan Sandler et al. profile →
  9. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
    2020 405 citations Robert M. Jotte, Federico Cappuzzo et al. Journal of Thoracic Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Alan Sandler 17.9k 15.6k 5.9k 3.3k 2.0k 163 23.8k
Mark A. Socinski 15.1k 0.8× 14.6k 0.9× 4.9k 0.8× 3.0k 0.9× 1.7k 0.8× 518 22.3k
Fabrice Barlési 15.4k 0.9× 13.4k 0.9× 5.1k 0.9× 3.3k 1.0× 2.7k 1.4× 570 22.1k
Martin Reck 17.5k 1.0× 13.7k 0.9× 4.5k 0.8× 3.2k 1.0× 2.7k 1.3× 402 22.9k
Martin Reck 14.2k 0.8× 13.4k 0.9× 4.4k 0.7× 3.5k 1.1× 2.4k 1.2× 339 20.3k
Joachim von Pawel 17.7k 1.0× 16.9k 1.1× 7.2k 1.2× 3.2k 1.0× 952 0.5× 254 25.0k
Johan Vansteenkiste 12.9k 0.7× 13.2k 0.8× 4.4k 0.7× 2.9k 0.9× 1.7k 0.9× 169 18.6k
Lesley Seymour 13.8k 0.8× 13.6k 0.9× 5.3k 0.9× 3.8k 1.1× 1.2k 0.6× 258 22.2k
Federico Cappuzzo 16.9k 0.9× 16.9k 1.1× 7.0k 1.2× 4.3k 1.3× 1.6k 0.8× 360 24.6k
Luis Paz‐Ares 13.2k 0.7× 11.4k 0.7× 7.6k 1.3× 4.2k 1.3× 2.2k 1.1× 690 23.0k
Suresh S. Ramalingam 15.5k 0.9× 14.5k 0.9× 8.8k 1.5× 4.2k 1.3× 2.6k 1.3× 593 25.5k

Countries citing papers authored by Alan Sandler

Since Specialization
Citations

This map shows the geographic impact of Alan Sandler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Sandler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Sandler more than expected).

Fields of papers citing papers by Alan Sandler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Sandler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Sandler. The network helps show where Alan Sandler may publish in the future.

Co-authorship network of co-authors of Alan Sandler

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Sandler. A scholar is included among the top collaborators of Alan Sandler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Sandler. Alan Sandler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Patil, Namrata S., Wei Zou, Simonetta Mocci, et al.. (2021). C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients. PLoS ONE. 16(2). e0246486–e0246486. 7 indexed citations
2.
Claret, Laurent, Jin Y. Jin, Charles Ferté, et al.. (2018). A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics. Clinical Cancer Research. 24(14). 3292–3298. 53 indexed citations
3.
Papadimitrakopoulou, Vassiliki A., Manuel Cobo, Rodolfo Bordoni, et al.. (2018). OA05.07 IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC. Journal of Thoracic Oncology. 13(10). S332–S333. 102 indexed citations
4.
Bonomi, Philip, Gideon M. Blumenthal, Andrea Stern Ferris, et al.. (2018). Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria. Journal of Thoracic Oncology. 13(6). 748–751. 10 indexed citations
5.
Spigel, David R., Jamie E. Chaft, Scott Gettinger, et al.. (2018). FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC. Journal of Thoracic Oncology. 13(11). 1733–1742. 114 indexed citations
6.
Kowanetz, Marcin, Wei Zou, David S. Shames, et al.. (2017). OA20.01 Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients. Journal of Thoracic Oncology. 12(1). S321–S322. 61 indexed citations
7.
Cappuzzo, Federico, Martin Reck, Vassiliki A. Papadimitrakopoulou, et al.. (2017). P3.02c-038 First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naïve Patients with Advanced NSCLC: A Phase III Clinical Program. Journal of Thoracic Oncology. 12(1). S1296–S1297. 1 indexed citations
8.
Wakelee, Heather A., Nasser K. Altorki, Eric Vallières, et al.. (2017). P3.02c-050 IMpower010: Phase III Study of Atezolizumab vs BSC after Adjuvant Chemotherapy in Patients with Completely Resected NSCLC. Journal of Thoracic Oncology. 12(1). S1305–S1305. 2 indexed citations
9.
Herbst, Roy S., Filippo de Marinis, Jacek Jassem, et al.. (2016). PS01.56: IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1–Selected Chemotherapy-Naive NSCLC Patients. Journal of Thoracic Oncology. 11(11). S304–S305. 4 indexed citations
10.
Jotte, Robert M., Mark A. Socinski, Martin Reck, et al.. (2016). PS01.53: First-Line Atezolizumab Plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program. Journal of Thoracic Oncology. 11(11). S302–S303. 4 indexed citations
11.
Gordon, Michael S., Roy S. Herbst, Leora Horn, et al.. (2016). PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study. Journal of Thoracic Oncology. 11(11). S309–S310. 2 indexed citations
12.
Lammers, Philip E., Yu Shyr, Alan Sandler, et al.. (2014). Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer. Journal of Thoracic Oncology. 9(4). 559–562. 20 indexed citations
13.
López-Chávez, Ariel, Larry Leon, Joan H. Schiller, et al.. (2012). Bevacizumab Maintenance in Patients with Advanced Non–Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group 4599 Study: Results of An Exploratory Analysis. Journal of Thoracic Oncology. 7(11). 1707–1712. 41 indexed citations
14.
Sandler, Alan, Jing Yi, Suzanne E. Dahlberg, et al.. (2010). Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(9). 1416–1423. 125 indexed citations
15.
16.
Chen, Heidi, Shuo Chen, Roy S. Herbst, et al.. (2009). Classification by Mass Spectrometry Can Accurately and Reliably Predict Outcome in Patients with Non-small Cell Lung Cancer Treated with Erlotinib-Containing Regimen. Journal of Thoracic Oncology. 4(6). 689–696. 23 indexed citations
17.
Rothenberg, Mace L., et al.. (2007). Phase I dose-escalation study of the anti-IGF-IR recombinant human IgG1 monoclonal antibody (Mab) IMC-A12, administered every other week to patients with advanced solid tumors. Molecular Cancer Therapeutics. 6. 17 indexed citations
18.
Blumenschein, George R., Alan Sandler, Timothy J. O’Rourke, et al.. (2007). PD3-3-7: Safety and Pharmacokinetics (PK) of AMG 706 With Carboplatin/Paclitaxel (C/P) and/or Panitumumab for the treatment of patients with advanced non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S469–S469. 7 indexed citations
19.
20.
Sandler, Alan. (2002). Irinotecan therapy for small-cell lung cancer.. PubMed. 16(4). 419–25, 428, 433; discussion 433. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark A. Socinski Breakdown of academic impact, for papers by Fabrice Barlési Breakdown of academic impact, for papers by Martin Reck Breakdown of academic impact, for papers by Martin Reck Breakdown of academic impact, for papers by Joachim von Pawel Breakdown of academic impact, for papers by Johan Vansteenkiste Breakdown of academic impact, for papers by Lesley Seymour Breakdown of academic impact, for papers by Federico Cappuzzo Breakdown of academic impact, for papers by Luis Paz‐Ares Breakdown of academic impact, for papers by Suresh S. Ramalingam
Rankless by CCL
2026